News

Alcon Laboratories announced that it has entered into a definitive agreement to acquire LenSx Lasers Inc., a privately held company located in Aliso Viejo, CA, that developed the first femtosecond laser to receive FDA clearance for use as a part of cataract surgery.

After 4 years of follow-up in a clinical trial, the angle-supported foldable acrylic phakic IOL is continuing to provide patients treated for moderate to high myopia with good visual acuity thanks to accurate predictability, a stable refractive outcome, and good safety.

Interim results from analyses of data collected in the ongoing LASIK in U.S. Naval Aviator Study show advances in excimer and femtosecond laser technology are contributing to better clinical results.

Since its earliest days, the Jules Stein Eye Institute at the University of California-Los Angeles has been known as a center for vision science research, with the goal of preserving and restoring eyesight.

Long-term follow-up in a cohort of eyes with the dual-optic accommodating IOL implanted supports its use as a viable option for presbyopic correction after cataract surgery.

Initial clinical results indicate the safety and efficacy of Descemet's membrane endothelial keratoplasty as a minimally invasive alternative for eyes requiring transplantation because of dysfunctional endothelium.

In the interest of providing both good-quality vision in addition to a full range of functional visual acuity for patients interested in a presbyopic IOL, the latest aspheric version of an accommodating IOL may be considered a better option relative to its multifocal competitors.

Intraoperative wavefront aberrometry using a proprietary system demonstrates the ability to measure refractive error accurately in aphakic eyes and represents technology that may improve accuracy of IOL power outcomes after cataract surgery.

Bausch + Lomb recently purchased the assets and U.S. rights for ganciclovir ophthalmic gel 0.15% from Sirion Therapeutics.

A mix-and-match approach to multi-focal IOL implantation using lenses based on two different optical principles provides excellent functional outcomes.

The author has always thought that advanced machines could not replace humans - until recently.

After enduring a week-long 21.2% pay cut, ophthalmologists and other physicians who see Medicare patients will receive a 2.2% pay increase, retroactive to June 1 through Nov. 30.

Robert E. Grant will join Bausch + Lomb on August 1 as its chief executive officer and president of the company's global surgical business.

The CE mark has been granted for a range of changes to an implantable contact lens (Visian Implantable Collamer Lens, STAAR Surgical Co.).

The FDA has approved the marketing of an accommodating IOL (Crystalens AO, Bausch + Lomb) in quarter-diopter steps in the United States.

Six organizations launched an e-learning Web site(www.actioned.org)for a wide range of eye-care professionals.

A surgical microscope (OPMI Lumera 700, Carl Zeiss Meditec) has received a "red dot design award" in product design from a 30-member international jury of the Design Zentrum Nordrhein Westfalen, Essen, Germany.

A proprietary spectral-domain optical coherence tomography (SD-OCT) device (iVue, Optovue) has received FDA 510(k) clearance.

The FDA has awarded 510(k) clearance to a proprietary laser system (LensAR, LensAR Inc.) for use for anterior capsulotomy during cataract surgery.

Valeant Pharmaceuticals International announced the completion of its acquisition of Aton Pharma Inc., headquartered in Lawrenceville, NJ.

Joan W. Miller, MD, has received the 2010 Joseph B. Martin Dean's Leadership Award for the Advancement of Women Faculty at Harvard Medical School.

Bausch + Lomb has purchased the assets and U.S. rights for ganciclovir ophthalmic gel 0.15% (Zirgan) from Sirion Therapeutics Inc., announced Bausch + Lomb in a press release.

Gatifloxacin ophthalmic solution 0.5% (Zymaxid, Allergan) is expected to be available to U.S. physicians and patients this month, according to the manufacturer.

Based on available evidence, intracameral cefuroxime represents the best, safest, and most effective antimicrobial agent to use for prophylaxis of postcataract surgery endophthalmitis.

Bromfenac ophthalmic solution 0.09% is effective for preventing pseudophakic cystoid macular edema when instilled 3 days before phacoemulsification and IOL implantation and then following surgery.

Has the time come for a widespread adoption of telemedicine screening for retinopathy of prematurity?

Ketorolac tromethamine ophthalmic solution 0.45%, a third-generation formulation of the nonsteroidal anti-inflammatory drug, had a highly beneficial effect on visual acuity after cataract surgery in a recent study.

A post hoc analysis of data collected in two published, pivotal clinical trials demonstrates that in addition to its efficacy for treating inflammation following ocular surgery, loteprednol etabonate ophthalmic suspension 0.5% provides statistically significant relief of postoperative pain and other symptoms.

Pre- and postoperative treatment with the potent corticosteroid difluprednate ophthalmic solution 0.05% significantly improves outcomes after cataract surgery compared with use of prednisolone acetate ophthalmic suspension 1% and so results in patient satisfaction.

Author discusses finer points of ophthalmologists who dabbled in politics.